RESUMEN
OBJECTIVE: For the treatment of HIV-1-related brain disease and for the prevention of the brain becoming a viral reservoir, it is important that antiretroviral agents reach sufficient concentrations in the CNS. To date, human brain pharmacokinetic data are solely derived from lumbar cerebrospinal fluid (CSF) and mostly originate from single samples. DESIGN: We determined concentrations of antiretroviral drugs in serial samples of ventricular CSF and compared these to the concentrations in serum and lumbar CSF of these patients. METHODS: Two treatment-naïve HIV-1-infected patients received external ventricular drainage for obstructive hydrocephalus. Starting with a combination antiretroviral regimen (cART), ventricular CSF, and subsequently lumbar CSF, with parallel serum, was frequently collected. Drug concentrations were determined and CSF-to-serum ratios were calculated. RESULTS: High concentrations, resulting in high CSF-to-serum ratios, were found in the ventricular CSF of the three substances zidovudine, lamivudine and indinavir, whereas this was not observed for stavudine, ritonavir, saquinavir and efavirenz. Concentrations of zidovudine and lamivudine were up to four times greater in CSF from the ventricles than in lumbar CSF of the same patient. The zidovudine concentrations in the ventricular CSF exceeded serum concentrations by a factor of 1.4. CONCLUSION: Unexpectedly high concentrations of some antiretrovirals in the ventricular CSF, the site close to the brain parenchyma where HIV is located, should be considered when the cART regimen is aiming at CNS viral replication.
Asunto(s)
Fármacos Anti-VIH/líquido cefalorraquídeo , Fármacos Anti-VIH/farmacocinética , Infecciones por VIH/tratamiento farmacológico , Lamivudine/líquido cefalorraquídeo , Lamivudine/farmacocinética , Zidovudina/líquido cefalorraquídeo , Zidovudina/farmacocinética , Complejo SIDA Demencia/prevención & control , Adulto , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/uso terapéutico , Quimioterapia Combinada , Infecciones por VIH/metabolismo , VIH-1/genética , Humanos , Lamivudine/sangre , Lamivudine/uso terapéutico , Masculino , ARN Viral/sangre , ARN Viral/líquido cefalorraquídeo , Punción Espinal , Estavudina/administración & dosificación , Estavudina/sangre , Estavudina/líquido cefalorraquídeo , Estavudina/uso terapéutico , Carga Viral , Zidovudina/sangre , Zidovudina/uso terapéuticoAsunto(s)
Fármacos Anti-VIH/farmacocinética , Antagonistas de los Receptores CCR5/administración & dosificación , Disfunción Cognitiva/tratamiento farmacológico , Infecciones por VIH/complicaciones , Imidazoles/farmacocinética , Fármacos Anti-VIH/líquido cefalorraquídeo , Fármacos Anti-VIH/uso terapéutico , Cognición/efectos de los fármacos , Disfunción Cognitiva/líquido cefalorraquídeo , Disfunción Cognitiva/etiología , Infecciones por VIH/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/genética , VIH-1/aislamiento & purificación , Humanos , Imidazoles/líquido cefalorraquídeo , Imidazoles/uso terapéutico , ARN Viral/líquido cefalorraquídeo , SulfóxidosRESUMEN
This study aimed to assess cerebrospinal fluid (CSF) drug concentrations and viral suppression in HIV-1-infected patients on ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. HIV-1-infected adults with suppressed plasma HIV-1 RNA who switched to ATV/r plus 3TC were studied. Total ATV and 3TC concentrations at the end of the dosing interval (C24h), using a validated LC-MS/MS method, and HIV-1 RNA were measured in paired CSF and plasma samples 12 weeks after switching. Ten individuals were included. Median (range) age was 42.5 (33-70) years, time on ART was 39.5 (11-197) months, and time with plasma HIV-1 RNA < 40 copies/mL was 15.5 (6-46) months. At baseline, CSF HIV-1 RNA was < 40 copies/mL in all patients. Twelve weeks after switching to ATV/r plus 3TC, HIV-1 RNA remained at < 40 copies/mL in both plasma and CSF in 9/10 patients. One patient with suboptimal adherence to ART had HIV-1 RNA rebound in both plasma and CSF. The median CSF-to-plasma concentration ratios of ATV and 3TC were 0.013 and 0.417, respectively. Median ATV C24h in CSF was 10.4 (3.7-33.4) ng/mL (in vitro ATV IC50 range, 1-11 ng/mL). Median 3TC C24h in CSF was 43.4 (16.2-99.3) ng/mL (in vitro 3TC IC50 range, 0.68-20.6 ng/mL). Most patients maintained HIV-1 RNA in CSF < 40 copies/mL despite CSF ATV C24h close to or within the IC50 range in the majority. ATV PK data in CSF should be considered and rigorous patient selection is advisable to assure effective CSF viral suppression with this two-drug simplification regimen.
Asunto(s)
Fármacos Anti-VIH/líquido cefalorraquídeo , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa/métodos , Infecciones por VIH/tratamiento farmacológico , Adulto , Anciano , Sulfato de Atazanavir/administración & dosificación , Sulfato de Atazanavir/líquido cefalorraquídeo , Quimioterapia Combinada/métodos , Femenino , VIH-1 , Humanos , Lamivudine/administración & dosificación , Lamivudine/líquido cefalorraquídeo , Masculino , Persona de Mediana Edad , ARN Viral/sangre , ARN Viral/líquido cefalorraquídeo , Ritonavir/administración & dosificación , Ritonavir/líquido cefalorraquídeo , Carga Viral/efectos de los fármacosRESUMEN
Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml-1 , P = 0.038 and 123 vs. 49 ng ml-1 , P = 0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.
Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/líquido cefalorraquídeo , Didesoxinucleósidos/administración & dosificación , Didesoxinucleósidos/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Adulto , Fármacos Anti-VIH/sangre , Cromatografía Líquida de Alta Presión , Didesoxinucleósidos/sangre , Esquema de Medicación , Monitoreo de Drogas/métodos , Femenino , Infecciones por VIH/sangre , Infecciones por VIH/líquido cefalorraquídeo , Infecciones por VIH/diagnóstico , Humanos , Italia , Masculino , Persona de Mediana Edad , Espectrometría de Masas en Tándem , Factores de Tiempo , Resultado del TratamientoRESUMEN
PURPOSE OF REVIEW: Neurocognitive disorders are not uncommon in HIV-positive patients but their pathogenesis is multifactorial and incompletely understood. After excluding contributing comorbidities, several factors may impair neurocognition including severe immune suppression, incomplete antiviral efficacy, drugs' persistent immune activation, vascular abnormalities, and drugs' neurotoxicity. The effectiveness of targeted antiretroviral strategies on these risk factors is unknown. RECENT FINDINGS: Recent studies support the idea that residual cerebrospinal fluid HIV RNA in the setting of plasma viral suppression is associated with compartmental immune activation but the link to neuronal damage is debated. Some authors have reported an incomplete antiviral efficacy in macrophage-derived cells but targeted antiretroviral regimen switches have not been performed. Additionally, improvements in neurocognition using drugs with better central nervous system penetration or maraviroc (associated with favorable immunological properties) have been observed in pilot studies. Trials evaluating specific interventions for cardiovascular health (including brain white matter abnormalities) and neurotoxicity of antiretrovirals are warranted. Central nervous system-targeted antiretroviral strategies are needed in patients with uncontrolled cerebrospinal HIV replication, and they may be suggested in subjects with low CD4 nadir, individuals carrying drug-resistant viruses, and those with compartmental immune activation.
Asunto(s)
Complejo SIDA Demencia/tratamiento farmacológico , Fármacos Anti-VIH/líquido cefalorraquídeo , Fármacos Anti-VIH/uso terapéutico , Sistema Nervioso Central/virología , Infecciones por VIH/tratamiento farmacológico , Trastornos Neurocognitivos/tratamiento farmacológico , Complejo SIDA Demencia/patología , Alquinos , Benzoxazinas/líquido cefalorraquídeo , Benzoxazinas/uso terapéutico , Encéfalo/virología , Líquido Cefalorraquídeo/virología , Ciclopropanos , VIH-1/efectos de los fármacos , Humanos , Neopterin/líquido cefalorraquídeo , Neopterin/uso terapéutico , Trastornos Neurocognitivos/patología , Trastornos Neurocognitivos/virologíaRESUMEN
A simple sample treatment procedure and sensitive liquid chromatography-tandem mass spectrometry method were developed for the simultaneous quantification of the concentrations of human immunodeficiency virus-1 integrase strand transfer inhibitors - raltegravir, dolutegravir and elvitegravir - in human plasma and cerebrospinal fluid (CSF). Plasma and CSF samples (20 µL each) were deproteinized with acetonitrile. Raltegravir-d3 was used as the internal standard. Chromatographic separation was achieved on an XBridge C18 column (50 × 2.1 mm i.d., particle size 3.5 µm) using acetonitrile-water (7:3, v/v) containing 0.1% formic acid as the mobile phase at a flow rate of 0.2 mL/min. The run time was 5 min. Calibration curves for all three drugs were linear in the range 5-1500 ng/mL for plasma and 1-200 ng/mL for CSF. The intra- and inter-day precision and accuracy of all three drugs in plasma were coefficient of variation (CV) <12.9% and 100.0 ± 12.2%, respectively, while those in CSF were CV <12.3% and 100.0 ± 7.9%, respectively. Successful validation under the same LC-MS/MS conditions for both plasma and CSF indicates this analytical method is useful for monitoring the levels of these integrase strand transfer inhibitors in the management of treatment of HIV-1 carriers.
Asunto(s)
Fármacos Anti-VIH , Cromatografía Líquida de Alta Presión/métodos , Compuestos Heterocíclicos con 3 Anillos , Quinolonas , Raltegravir Potásico , Espectrometría de Masas en Tándem/métodos , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Compuestos Heterocíclicos con 3 Anillos/sangre , Compuestos Heterocíclicos con 3 Anillos/líquido cefalorraquídeo , Humanos , Modelos Lineales , Oxazinas , Piperazinas , Piridonas , Quinolonas/sangre , Quinolonas/líquido cefalorraquídeo , Raltegravir Potásico/sangre , Raltegravir Potásico/líquido cefalorraquídeo , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Intranasal administration could be an attractive alternative route of administration for the delivery of drugs to the central nervous system (CNS). However, there are always doubts about the direct transport of therapeutics from nasal cavity to the CNS since there are only limited studies on the understanding of direct nose-to-brain transport. Therefore, this study aimed to (1) investigate the existence of nose-to-brain transport of intranasally administered HIV-1 replication inhibitor DB213 and (2) assess the direct nose-to-brain transport of unbound HIV-1 replication inhibitor DB213 quantitatively by a pharmacokinetic approach. Plasma samples were collected up to 6 h post-dosing after administration via intranasal or intravenous route at three bolus doses. In the brain-uptake study, the plasma, whole brain, and cerebrospinal fluid (CSF) were sampled between 15 min and 8 h post-dosing. All samples were analyzed with LC/MS/MS. Plasma, CSF, and brain concentration versus time profiles were analyzed with nonlinear mixed-effect modeling. Structural model building was performed by NONMEM (version VII, level 2.0). Intranasal administration showed better potential to deliver HIV-1 replication inhibitor DB213 to the brain with 290-fold higher brain to plasma ratio compared with intravenous administration. Based on that, a model with two absorption compartments (nose-to-systemic circulation and nose-to-brain) was developed and demonstrated 72.4% of total absorbed unbound HIV-1 replication inhibitor DB213 after intranasal administration was transported directly into the brain through nose-to-brain pathway.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Benzamidinas/farmacocinética , Encéfalo/metabolismo , Modelos Biológicos , Mucosa Nasal/metabolismo , Administración Intranasal , Administración Intravenosa , Animales , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Benzamidinas/administración & dosificación , Benzamidinas/sangre , Benzamidinas/líquido cefalorraquídeo , VIH-1/efectos de los fármacos , VIH-1/fisiología , Masculino , Modelos Animales , Ratas , Ratas Sprague-Dawley , Replicación Viral/efectos de los fármacosRESUMEN
Objectives: Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs. We compared darunavir concentrations in CSF when boosted by cobicistat versus ritonavir relative to plasma concentrations and with WT HIV-1 IC50 and IC90. Methods: An open, single-arm, sequential clinical trial (NCT02503462) where paired CSF and blood samples were taken from seven HIV-infected patients presenting with HIV-associated neurocognitive disorders (HAND) and treated with a darunavir/ritonavir (800/100 mg) once-daily regimen. Ritonavir was subsequently replaced by cobicistat and paired CSF and blood samples were obtained from the same patients after treatment with the darunavir/cobicistat (800/150 mg) once-daily regimen. Darunavir concentrations at the end of the dosing interval were quantified by LC-MS/MS. Results: The median (IQR) darunavir concentrations in CSF with ritonavir and cobicistat boosting were 16.4 ng/mL (8.6-20.3) and 15.9 ng/mL (6.7-31.6), respectively (P = 0.58). The median (IQR) darunavir CSF:plasma ratios with ritonavir and cobicistat boosting were 0.007 (0.006-0.012) and 0.011 (0.007-0.015), respectively (P = 0.16). Darunavir concentrations in CSF exceeded the darunavir IC50 and IC90 by a median of 9.2- and 6.7-fold with ritonavir boosting, and by 8.9- and 6.5-fold with cobicistat boosting, respectively. All patients had darunavir CSF concentrations above the target inhibitory concentrations and remained virologically suppressed in the CSF and plasma. Conclusions: This small study shows that cobicistat and ritonavir give comparable effective darunavir concentrations in CSF, thus suggesting that these boosters can be used interchangeably in once-daily darunavir regimens.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Cobicistat/uso terapéutico , Darunavir/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/uso terapéutico , Ritonavir/uso terapéutico , Adulto , Anciano , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Cobicistat/administración & dosificación , Cobicistat/sangre , Darunavir/sangre , Darunavir/uso terapéutico , Quimioterapia Combinada , Femenino , Inhibidores de la Proteasa del VIH/sangre , Inhibidores de la Proteasa del VIH/líquido cefalorraquídeo , VIH-1/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Ritonavir/administración & dosificación , Espectrometría de Masas en TándemRESUMEN
Adequate concentrations of efavirenz in the central nervous system (CNS) are necessary to suppress viral replication, but high concentrations may increase the likelihood of CNS adverse drug reactions. The aim of this investigation was to evaluate the efavirenz distribution in the cerebrospinal fluid (CSF) and the brain by using a physiologically based pharmacokinetic (PBPK) simulation for comparison with rodent and human data. The efavirenz CNS distribution was calculated using a permeability-limited model on a virtual cohort of 100 patients receiving efavirenz (600 mg once daily). Simulation data were then compared with human data from the literature and with rodent data. Wistar rats were administered efavirenz (10 mg kg of body weight-1) once daily over 5 weeks. Plasma and brain tissue were collected for analysis via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The median maximum concentrations of drug (Cmax) were predicted to be 3,184 ng ml-1 (interquartile range [IQR], 2,219 to 4,851 ng ml-1), 49.9 ng ml-1 (IQR, 36.6 to 69.7 ng ml-1), and 50,343 ng ml-1 (IQR, 38,351 to 65,799 ng ml-1) in plasma, CSF, and brain tissue, respectively, giving a tissue-to-plasma ratio of 15.8. Following 5 weeks of oral dosing of efavirenz (10 mg kg-1), the median plasma and brain tissue concentrations in rats were 69.7 ng ml-1 (IQR, 44.9 to 130.6 ng ml-1) and 702.9 ng ml-1 (IQR, 475.5 to 1,018.0 ng ml-1), respectively, and the median tissue-to-plasma ratio was 9.5 (IQR, 7.0 to 10.9). Although it is useful, measurement of CSF concentrations may give an underestimation of the penetration of antiretrovirals into the brain. The limitations associated with obtaining tissue biopsy specimens and paired plasma and CSF samples from patients make PBPK modeling an attractive tool for probing drug distribution.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Benzoxazinas/farmacocinética , Encéfalo/metabolismo , Modelos Estadísticos , Administración Oral , Alquinos , Animales , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Benzoxazinas/sangre , Benzoxazinas/líquido cefalorraquídeo , Simulación por Computador , Ciclopropanos , Esquema de Medicación , Cálculo de Dosificación de Drogas , Humanos , Masculino , Proteínas del Tejido Nervioso/metabolismo , Unión Proteica , Ratas , Ratas Wistar , Distribución TisularAsunto(s)
Fármacos Anti-VIH/líquido cefalorraquídeo , Cobicistat/líquido cefalorraquídeo , Emtricitabina/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Quinolonas/líquido cefalorraquídeo , Tenofovir/líquido cefalorraquídeo , Adulto , Terapia Antirretroviral Altamente Activa/métodos , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Fármacos Anti-VIH/líquido cefalorraquídeo , Líquido Cefalorraquídeo/metabolismo , Emtricitabina/líquido cefalorraquídeo , Inhibidores de la Proteasa del VIH/uso terapéutico , Proteasa del VIH/metabolismo , VIH-1/efectos de los fármacos , Tenofovir/líquido cefalorraquídeo , Fármacos Anti-VIH/uso terapéutico , Barrera Hematoencefálica/metabolismo , Líquido Cefalorraquídeo/virología , Emtricitabina/uso terapéutico , Femenino , Inhibidores de la Proteasa del VIH/líquido cefalorraquídeo , VIH-1/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Profármacos/uso terapéutico , ARN Viral/líquido cefalorraquídeo , Tenofovir/uso terapéuticoRESUMEN
BACKGROUND: Lopinavir/ritonavir (LPV/r) monotherapy is used in selected virologically suppressed HIV-infected patients. Some would prefer a once-daily (OD) dose instead of the usual twice-daily dose to favour adherence. However, trough concentrations of the drug in blood and particularly in cerebrospinal fluid (CSF) may not be adequate to maintain viral suppression. METHODS: Prospective, open-label pilot study to evaluate the efficacy and safety of LPV/r monotherapy OD. HIV-1-infected patients, virologically suppressed for at least 6 months were enrolled. HIV viral load (VL) was determined at baseline and at weeks 4, 8, 12, 16, 24, 36 and 48. Lumbar puncture was performed in a subgroup of patients to evaluate CSF VL and CSF LPV concentrations. RESULTS: A total of 21 patients were included. At week 48, 85.7% (n=18) showed viral suppression (VL<40 copies/ml). Two patients had viral failure (9.5%) and a third was withdrawn from the study because of gastrointestinal symptoms. Nine patients were enrolled in the substudy. CSF VL was <40 copies/ml in all cases. Median (range) LPV concentration was 9.78 ng/ml (1.93-78.3) in CSF and 1,970 (154-16,700) ng/ml in plasma; the CSF/plasma ratio was 0.004 (0.001-0.186). CONCLUSIONS: In this small pilot study, LPV/r monotherapy OD maintained plasma HIV RNA suppression at 48 weeks in most patients, with no cases of CSF viral escape. However, CSF LPV concentrations were close to the 50% inhibitory concentration threshold in several patients; hence, this intervention should be avoided in patients with advanced immune suppression and/or those individuals presenting with significant comorbidities such as hepatitis C coinfection.
Asunto(s)
Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Lopinavir/sangre , Lopinavir/líquido cefalorraquídeo , Ritonavir/uso terapéutico , Adulto , Fármacos Anti-VIH/uso terapéutico , Esquema de Medicación , Combinación de Medicamentos , Femenino , Infecciones por VIH/sangre , Humanos , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Insuficiencia del TratamientoRESUMEN
Efavirenz (EFV) is principally metabolized by CYP2B6 to 8-hydroxy-efavirenz (8OH-EFV) and to a lesser extent by CYP2A6 to 7-hydroxy-efavirenz (7OH-EFV). So far, most metabolite profile analyses have been restricted to 8OH-EFV, 7OH-EFV, and EFV-N-glucuronide, even though these metabolites represent a minor percentage of EFV metabolites present in vivo. We have performed a quantitative phase I and II metabolite profile analysis by tandem mass spectrometry of plasma, cerebrospinal fluid (CSF), and urine samples in 71 human immunodeficiency virus patients taking efavirenz, prior to and after enzymatic (glucuronidase and sulfatase) hydrolysis. We have shown that phase II metabolites constitute the major part of the known circulating efavirenz species in humans. The 8OH-EFV-glucuronide (gln) and 8OH-EFV-sulfate (identified for the first time) in humans were found to be 64- and 7-fold higher than the parent 8OH-EFV, respectively. In individuals (n = 67) genotyped for CYP2B6, 2A6, and CYP3A metabolic pathways, 8OH-EFV/EFV ratios in plasma were an index of CYP2B6 phenotypic activity (P < 0.0001), which was also reflected by phase II metabolites 8OH-EFV-glucuronide/EFV and 8OH-EFV-sulfate/EFV ratios. Neither EFV nor 8OH-EFV, nor any other considered metabolites in plasma were associated with an increased risk of central nervous system (CNS) toxicity. In CSF, 8OH-EFV levels were not influenced by CYP2B6 genotypes and did not predict CNS toxicity. The phase II metabolites 8OH-EFV-gln, 8OH-EFV-sulfate, and 7OH-EFV-gln were present in CSF at 2- to 9-fold higher concentrations than 8OH-EFV. The potential contribution of known and previously unreported EFV metabolites in CSF to the neuropsychological effects of efavirenz needs to be further examined in larger cohort studies.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Benzoxazinas/efectos adversos , Benzoxazinas/farmacocinética , Infecciones por VIH/tratamiento farmacológico , Metabolómica/métodos , Inhibidores de la Transcriptasa Inversa/farmacocinética , Espectrometría de Masas en Tándem , Alquinos , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Fármacos Anti-VIH/orina , Benzoxazinas/sangre , Benzoxazinas/líquido cefalorraquídeo , Benzoxazinas/orina , Ciclopropanos , Citocromo P-450 CYP2A6/genética , Citocromo P-450 CYP2A6/metabolismo , Citocromo P-450 CYP2B6/genética , Citocromo P-450 CYP2B6/metabolismo , Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Genotipo , Glucurónidos/sangre , Glucurónidos/líquido cefalorraquídeo , Glucurónidos/orina , Infecciones por VIH/diagnóstico , Infecciones por VIH/metabolismo , Humanos , Hidroxilación , Fase I de la Desintoxicación Metabólica , Fase II de la Desintoxicación Metabólica , Síndromes de Neurotoxicidad/etiología , Síndromes de Neurotoxicidad/genética , Síndromes de Neurotoxicidad/metabolismo , Fenotipo , Inhibidores de la Transcriptasa Inversa/efectos adversos , Inhibidores de la Transcriptasa Inversa/sangre , Inhibidores de la Transcriptasa Inversa/líquido cefalorraquídeo , Inhibidores de la Transcriptasa Inversa/orina , Medición de Riesgo , Sulfatos/sangre , Sulfatos/líquido cefalorraquídeo , Sulfatos/orinaRESUMEN
Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).
Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Proteínas de Neoplasias/genética , Pirrolidinonas/farmacocinética , Pirrolidinonas/uso terapéutico , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2 , Transportadoras de Casetes de Unión a ATP/metabolismo , Fármacos Anti-VIH/líquido cefalorraquídeo , Regulación de la Expresión Génica , Variación Genética , Genotipo , Infecciones por VIH/líquido cefalorraquídeo , Humanos , Proteínas de Neoplasias/metabolismo , Pirrolidinonas/líquido cefalorraquídeo , Raltegravir PotásicoRESUMEN
HIV-1 protease inhibitors (PIs) exhibit different protein binding affinities and achieve variable plasma and tissue concentrations. Degree of plasma protein binding may impact central nervous system penetration. This cross-sectional study assessed cerebrospinal fluid (CSF) unbound PI concentrations, HIV-1 RNA, and neopterin levels in subjects receiving either ritonavir-boosted darunavir (DRV), 95% plasma protein bound, or atazanavir (ATV), 86% bound. Unbound PI trough concentrations were measured using rapid equilibrium dialysis and liquid chromatography/tandem mass spectrometry. Plasma and CSF HIV-1 RNA and neopterin were measured by Ampliprep/COBAS® Taqman® 2.0 assay (Roche) and enzyme-linked immunosorbent assay (ALPCO), respectively. CSF/plasma unbound drug concentration ratio was higher for ATV, 0.09 [95% confidence interval (CI) 0.06-0.12] than DRV, 0.04 (95%CI 0.03-0.06). Unbound CSF concentrations were lower than protein adjusted wild-type inhibitory concentration-50 (IC50 ) in all ATV and 1 DRV-treated subjects (P < 0.001). CSF HIV-1 RNA was detected in 2/15 ATV and 4/15 DRV subjects (P = 0.65). CSF neopterin levels were low and similar between arms. ATV relative to DRV had higher CSF/plasma unbound drug ratio. Low CSF HIV-1 RNA and neopterin suggest that both regimens resulted in CSF virologic suppression and controlled inflammation.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Oligopéptidos/farmacocinética , Piridinas/farmacocinética , Sulfonamidas/farmacocinética , Adulto , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Sulfato de Atazanavir , Proteínas Sanguíneas/metabolismo , Darunavir , Quimioterapia Combinada , Femenino , Infecciones por VIH/sangre , Infecciones por VIH/líquido cefalorraquídeo , Infecciones por VIH/metabolismo , Infecciones por VIH/virología , VIH-1/genética , Humanos , Masculino , Persona de Mediana Edad , Neopterin/sangre , Neopterin/líquido cefalorraquídeo , Oligopéptidos/administración & dosificación , Oligopéptidos/sangre , Oligopéptidos/líquido cefalorraquídeo , Unión Proteica , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/líquido cefalorraquídeo , ARN Viral/sangre , ARN Viral/líquido cefalorraquídeo , Ritonavir/administración & dosificación , Sulfonamidas/administración & dosificación , Sulfonamidas/sangre , Sulfonamidas/líquido cefalorraquídeoRESUMEN
Efavirenz (EFV) is one of the most commonly prescribed antiretroviral drugs (ARVs) for the treatment of HIV. Highly protein-bound drugs, like EFV, have limited central nervous system (CNS) penetration when measured using total drug concentration gradients between blood plasma (BP) and cerebrospinal fluid (CSF). However, the more relevant pharmacologically active protein-free drug concentrations are rarely assessed directly in clinical studies. Using paired BP and CSF samples obtained from 13 subjects on an EFV-containing regimen, both the protein-free and total concentrations of EFV were determined. Despite a median (interquartile range [IQR]) total EFV BP/CSF concentration ratio of 134 (116 to 198), the protein-free EFV BP/CSF concentration ratio was 1.20 (0.97 to 2.12). EFV median (IQR) protein binding was 99.78% (99.74 to 99.80%) in BP and 76.19% (74.47 to 77.15%) in CSF. In addition, using the law of mass action and an in vitro-derived EFV-human serum albumin dissociation constant, we have demonstrated that the predicted median (IQR) protein-free concentration in BP, 4.59 ng/ml (4.02 to 9.44 ng/ml), compared well to that observed in BP, 4.77 ng/ml (3.68 to 6.75 ng/ml). Similar results were also observed in CSF and seminal plasma. This method provides a useful predictive tool for estimating protein binding in varied anatomic compartments. Our results of equivalent protein-free EFV concentrations in BP and CSF do not support prior concerns of the CNS as a pharmacological sanctuary from EFV. As CSF penetration of ARVs may increase our understanding of HIV-associated neurological dysfunction and antiretroviral effect, assessment of protein-free CSF concentrations of other highly protein-bound ARVs is warranted.
Asunto(s)
Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Benzoxazinas/sangre , Benzoxazinas/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , VIH-1 , Albúmina Sérica/metabolismo , Adulto , Alquinos , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Benzoxazinas/farmacocinética , Benzoxazinas/uso terapéutico , Ciclopropanos , Infecciones por VIH/sangre , Infecciones por VIH/líquido cefalorraquídeo , Infecciones por VIH/virología , Humanos , Cinética , Valor Predictivo de las Pruebas , Unión Proteica , Semen/químicaRESUMEN
Severe HIV-associated neurocognitive disorders (HAND), such as HIV-associated dementia, and opportunistic CNS infections are now rare complications of HIV infection due to comprehensive highly active antiretroviral therapy (HAART). By contrast, mild to moderate neurocognitive disorders remain prevalent, despite good viral control in peripheral compartments. HIV infection seems to provoke chronic CNS injury that may evade systemic HAART. Penetration of antiretroviral drugs across the blood-brain barrier might be crucial for the treatment of HAND. This review identifies and evaluates the available clinical evidence on CSF penetration properties of antiretroviral drugs, addressing methodological issues and discussing the clinical relevance of drug concentration assessment. Although a substantial number of studies examined CSF concentrations of antiretroviral drugs, there is a need for adequate, well designed trials to provide more valid drug distribution profiles. Neuropsychological benefits and neurotoxicity of potentially CNS-active drugs require further investigation before penetration characteristics will regularly influence therapeutic strategies and outcome.
Asunto(s)
Complejo SIDA Demencia/tratamiento farmacológico , Fármacos Anti-VIH/líquido cefalorraquídeo , Infecciones por VIH/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Animales , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa/métodos , Barrera Hematoencefálica/metabolismo , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/virología , Infecciones por VIH/complicaciones , HumanosRESUMEN
Efavirenz (EFV) is one of the most commonly prescribed antiretrovirals for use in the treatment of human immunodeficiency virus (HIV) infection. EFV is extensively metabolized by cytochrome P450 to a number of oxygenated products; however, the pharmacologic activity and distribution of these metabolites in anatomic compartments have yet to be explored. The systemic distribution of EFV oxidative metabolites was examined in blood plasma, seminal plasma, and cerebrospinal fluid from subjects on an EFV-based regimen. The 8-hydroxy EFV metabolite was detected in blood plasma, seminal plasma, and cerebrospinal fluid, with median concentrations of 314.5 ng/ml, 358.5 ng/ml, and 3.37 ng/ml, respectively. In contrast, 7-hydroxy and 8,14-hydroxy EFV were only detected in blood plasma and seminal plasma with median concentrations of 8.84 ng/ml and 10.23 ng/ml, and 5.63 ng/ml and 5.43 ng/ml, respectively. Interestingly, protein-free concentrations of metabolites were only detectable in seminal plasma, where a novel dihdyroxylated metabolite of EFV was also detected. This accumulation of protein-free EFV metabolites was demonstrated to be the result of differential protein binding in seminal plasma compared with that of blood plasma. In addition, the oxidative metabolites of EFV did not present with any significant pharmacologic activity toward HIV-1 as measured using an HIV green fluorescent protein single-round infectivity assay. This study is the first to report the physiologic distribution of metabolites of an antiretroviral into biologic compartments that the virus is known to distribute and to examine their anti-HIV activity. These data suggest that the male genital tract may be a novel compartment that should be considered in the evaluation of drug metabolite exposure.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Benzoxazinas/farmacocinética , Transcriptasa Inversa del VIH/antagonistas & inhibidores , VIH-1/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa/farmacocinética , Semen/metabolismo , Adulto , Anciano , Alquinos , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Benzoxazinas/sangre , Benzoxazinas/líquido cefalorraquídeo , Biotransformación , Linfocitos T CD4-Positivos/virología , Células Cultivadas , Ciclopropanos , Sistema Enzimático del Citocromo P-450/metabolismo , Femenino , Transcriptasa Inversa del VIH/metabolismo , VIH-1/enzimología , VIH-1/crecimiento & desarrollo , Humanos , Hidroxilación , Isoenzimas , Masculino , Microsomas Hepáticos/enzimología , Persona de Mediana Edad , Oxidación-Reducción , Unión Proteica , Proteínas Recombinantes/metabolismo , Inhibidores de la Transcriptasa Inversa/sangre , Inhibidores de la Transcriptasa Inversa/líquido cefalorraquídeo , Distribución TisularRESUMEN
Despite combination antiretroviral therapies (cARTs), a significant proportion of HIV-infected patients develop HIV-associated neurocognitive disorders (HAND). Ongoing viral replication in the central nervous system (CNS) caused by poor brain penetration of cART may contribute to HAND. However, it has also been proposed that the toxic effects of long-term cART may contribute to HAND. A better understanding of the neurotoxic potential of cART is critically needed in light of the use of CNS-penetrating cARTs to contend with the virus reservoir in the brain. The efavirenz (EFV) metabolites 7-hydroxyefavirenz (7-OH-EFV) and 8-hydroxyefavirenz (8-OH-EFV) were synthesized and purified, and their chemical structures were confirmed by mass spectrometry and NMR. The effects of EFV, 7-OH-EFV, and 8-OH-EFV on calcium, dendritic spine morphology, and survival were determined in primary neurons. EFV, 7-OH-EFV, and 8-OH-EFV each induced neuronal damage in a dose-dependent manner. However, 8-OH-EFV was at least an order of magnitude more toxic than EFV or 7-OH-EFV, inducing considerable damage to dendritic spines at a 10 nM concentration. The 8-OH-EFV metabolite evoked calcium flux in neurons, which was mediated primarily by L-type voltage-operated calcium channels (VOCCs). Blockade of L-type VOCCs protected dendritic spines from 8-OH-EFV-induced damage. Concentrations of EFV and 8-OH-EFV in the cerebral spinal fluid of HIV-infected subjects taking EFV were within the range that damaged neurons in culture. These findings demonstrate that the 8-OH metabolite of EFV is a potent neurotoxin and highlight the importance of directly determining the effects of antiretroviral drugs and drug metabolites on neurons and other brain cells.
Asunto(s)
Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/metabolismo , Benzoxazinas/efectos adversos , Benzoxazinas/metabolismo , Espinas Dendríticas/efectos de los fármacos , Alquinos , Animales , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/líquido cefalorraquídeo , Apoptosis/efectos de los fármacos , Benzoxazinas/sangre , Benzoxazinas/líquido cefalorraquídeo , Calcio/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ciclopropanos , Citosol/efectos de los fármacos , Citosol/metabolismo , Espinas Dendríticas/metabolismo , Espinas Dendríticas/patología , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ratas , Espectrometría de Masas en TándemRESUMEN
We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (n = 24) and plasma (n = 25) samples. The median plasma efavirenz concentration was 3,718 ng/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng/ml (range, 7.3 to 22.3). The CSF/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.